Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01360554 · ClinicalTrials.gov registry record · Phase 3
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 878
- Enrollment target
NCT01360554 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 878 participants.
The verdict
NCT01360554, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 878 participants
- Enrollment target
Study Summary
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.
Interventions
- DRUG Dacomitinib (PF-00299804)
- DRUG Active Comparator (erlotinib)
- DRUG Placebo erlotinib
- DRUG Placebo PF00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 878 participants |
| Start Date | 2011-06-16 |
| Est. Completion | 2015-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01360554
The ClinicalTrials.gov registry entry for NCT01360554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 878 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dacomitinib (PF-00299804) is the first listed.
NCT01360554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01360554 about?
NCT01360554 is a clinical study titled "ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer". This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary obj...
What is the current status of trial NCT01360554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 878 participants. The study started on 2011-06-16. Estimated completion is 2015-09-14.
What interventions are being tested in trial NCT01360554?
The interventions under investigation include: Dacomitinib (PF-00299804) (DRUG), Active Comparator (erlotinib) (DRUG), Placebo erlotinib (DRUG), Placebo PF00299804 (DRUG).
Who is sponsoring clinical trial NCT01360554?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.